The company has entered into an exclusive option agreement with Cedars-Sinai to continue investigating the clinical utility of L-glutamine oral powder in combination with chemotherapy, as a potential treatment for Pancreatic Ductal Adenocarcinoma (PDAC). PDAC is the most common type of pancreatic cancer and is notoriously difficult to treat, often presenting with late-stage diagnoses and limited therapeutic options. The collaboration with Cedars-Sinai researchers leverages the institution's premier oncological research capabilities alongside Emmaus' expertise in drug development for orphan diseases. In Phase 1 clinical trial, the combination of L-glutamine and gemcitabine/nab-paclitaxel resulted in a median OS of 22 months, which is near tripling of the median OS for gemcitabine/nab-paclitaxel itself (median 8.5 months). The results are published in Nature Cancer.